Sponsors

Tumour HER2 status assay

  •  

Ipsogen has launched MapQuant Dx HER2 test. Developed on the MapQuant Dx microarray diagnostic platform, MapQuant Dx HER2 measures a set of HER2-amplified genes that correlate with HER2 protein expression. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients.

MapQuant Dx HER2 is the second test to be developed on the MapQuant Dx platform, after the Genomic Grade launched by Ipsogen last year. As a result of the company’s experience in molecular diagnostics and to numerous research collaborations, it aims to continue to deliver innovative tests at an accelerated pace.
www.ipsogen.com

Other News

10 Year Plan’s ‘Innovator passports’ to boost MedTech

News

Jul 03, 2025
Genetic link between weight-loss jabs and pancreatitis investigated

News

Jul 01, 2025
Diatron launches new flagship clinical chemistry system

News

Jul 01, 2025
New research reveals enzyme's influence over cancer cells

News

Jul 01, 2025
IBMS welcomes Government Industrial Strategy

News

Jul 01, 2025
Updated Business Plan published by MHRA

News

Jul 01, 2025
PathAI DP platform receives FDA clearance for primary diagnosis

News

Jul 01, 2025
EVIDENT launches new CE-marked whole-slide scanner

News

Jun 27, 2025
MHRA to lead safe use of AI in global healthcare

News

Jun 27, 2025

Latest Issues

HORIBA UK Ltd

HORIBA Medical is a renowned specialist in the design and manufacture of automated in-vitro diagnostic systems for analysis in haematology, clinical chemistry, and haemostasis. From compact point of care (POC) solutions to high throughput laboratory systems, HORIBA Medical has successfully developed an array of analysers and data management...

Learn more »

Annual SHOT Symposium

Hilton Birmingham Metropole Hotel, B40 1P
11 July 2025